Risk‐adapted <scp>GVHD</scp> prophylaxis with post‐transplantation cyclophosphamide in adults after related, unrelated, and haploidentical transplantations

Abstract

The suggested risk-adapted PTCy-based prophylaxis is feasible and is associated with low GVHD incidence and mortality in all types of grafts. The study was registered on clinicaltrials.gov (NCT02294552).